Differentially expressed genes associated with cisplatin resistance in human ovarian adenocarcinoma cell line A2780

Cancer Letters

Volumn 309, Issue 1, 2011, Pages 11-18

  Solár, Peter ^a   Sytkowski, Arthur J ^b,c  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c IQVIA   (United States)

Author keywords

Cancer; Chemoresistance; Cisplatin; Ovarian; Subtractive hybridization

Indexed keywords

CISPLATIN;

ANXA2 GENE; APOPTOSIS; ARHGDIB GENE; ARTICLE; ASPH GENE; ATP2B1 GENE; CALCIUM HOMEOSTASIS; CANCER CELL; CANCER CELL CULTURE; CANCER RESISTANCE; CELL INVASION; CELLULAR STRESS RESPONSE; CFL2 GENE; CHROMATIN CONDENSATION; CLONE; CNAP1 GENE; CONTROLLED STUDY; COX2 GENE; DNAJC15 GENE; DRUG SENSITIVITY; FEMALE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ASSOCIATION; HSPCA GENE; HUMAN; HUMAN CELL; MBNL1 GENE; MMP10 GENE; NUCLEOTIDE SEQUENCE; OVARY ADENOCARCINOMA; PCDH18 GENE; PEG10 GENE; PRIORITY JOURNAL; PRTFDC1 GENE; RANBP2 GENE; SLC2A12 GENE; SSX2IP GENE; TCTE1L GENE; TMSB4X GENE; TRA1 GENE; USP8 GENE; VTA1 GENE; ZNF 294 GENE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CALCIUM-BINDING PROTEINS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; MATRIX METALLOPROTEINASE 10; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MIXED FUNCTION OXYGENASES; MOLECULAR CHAPERONES; MUSCLE PROTEINS; NEOPLASM INVASIVENESS; NUCLEAR PORE COMPLEX PROTEINS; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PLASMA MEMBRANE CALCIUM-TRANSPORTING ATPASES;

EID: 79959844133     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.05.008     Document Type: Article

References (49)

1. Tsuruo T., Naito M., Tomida A., Fujita N., Mashima T., Sakamoto H., Haga N. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci. 2003, 94:15-21.
2. Siddik Z.H. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265-7279.
3. Yuan Z.Q., Feldman R.I., Sussman G.E., Coppola D., Nicosia S.V., Cheng J.Q. AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance. J. Biol. Chem. 2003, 278:23432-23440.
4. Ferry K.V., Hamilton T.C., Johnson S.W. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem. Pharmacol. 2000, 60:1305-1313.
5. Selvakumaran M., Pisarcik D.A., Bao R., Yeung A.T., Hamilton T.C. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 2003, 63:1311-1316.
6. Parker R.J., Eastman A., Bostick-Bruton F., Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J. Clin. Invest. 1991, 87:772-777.
7. Roberts D., Schick J., Conway S., Biade S., Laub P.B., Stevenson J.P., Hamilton T.C., O'Dwyer P.J., Johnson S.W. Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells. Br. J. Cancer 2005, 92:1149-1158.
8. Li F., Meng L., Zhou J., Xing H., Wang S., Xu G., Zhu H., Wang B., Chen G., Lu Y.P., Ma D. Reversing chemoresistance in cisplatin-resistant human ovarian cancer cells: a role of c-Jun NH2-terminal kinase 1. Biochem. Biophys. Res. Commun. 2005, 335:1070-1077.
9. Yang X., Xing H., Gao Q., Chen G., Lu Y., Wang S., Ma D. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells. Gynecol. Oncol. 2005, 97:413-421.
10. Turchi J.J. Nitric oxide and cisplatin resistance: NO easy answers. Proc. Natl. Acad. Sci. USA 2006, 103:4337-4338.
11. Gosepath E.M., Eckstein N., Hamacher A., Servan K., von Jonquieres G., Lage H., Gyorffy B., Royer H.D., Kassack M.U. Acquired cisplatin resistance in the head-neck cancer cell line Cal27 is associated with decreased DKK1 expression and can partially be reversed by overexpression of DKK1. Int. J. Cancer 2008, 123:2013-2019.
12. Park K.S., Kim H.K., Lee J.H., Choi Y.B., Park S.Y., Yang S.H., Kim S.Y., Hong K.M. Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 2011, 136:493-502.
13. Noel E.E., Yeste-Velasco M., Mao X., Perry J., Kudahetti S.C., Li N.F., Sharp S., Chaplin T., Xue L., McIntyre A., Shan L., Powles T., Oliver R.T., Young B.D., Shipley J., Berney D.M., Joel S.P., Lu Y.J. The association of CCND1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. Am. J. Pathol. 2010, 176:2607-2615.
14. Jones M.B., Krutzsch H., Shu H., Zhao Y., Liotta L.A., Kohn E.C., Petricoin E.F. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2002, 2:76-84.
15. Sinha P., Hutter G., Kottgen E., Dietel M., Schadendorf D., Lage H. Search for novel proteins involved in the development of chemoresistance in colorectal cancer and fibrosarcoma cells in vitro using two-dimensional electrophoresis, mass spectrometry and microsequencing. Electrophoresis 1999, 20:2961-2969.
16. MacKeigan J.P., Clements C.M., Lich J.D., Pope R.M., Hod Y., Ting J.P. Proteomic profiling drug-induced apoptosis in non-small cell lung carcinoma: identification of RS/DJ-1 and RhoGDIalpha. Cancer Res. 2003, 63:6928-6934.
17. Shen J., Hughes C., Chao C., Cai J., Bartels C., Gessner T., Subjeck J. Coinduction of glucose-regulated proteins and doxorubicin resistance in Chinese hamster cells. Proc. Natl. Acad. Sci. USA 1987, 84:3278-3282.
18. Yun J., Tomida A., Nagata K., Tsuruo T. Glucose-regulated stresses confer resistance to VP-16 in human cancer cells through a decreased expression of DNA topoisomerase II. Oncol. Res. 1995, 7:583-590.
19. Yamamoto K., Okamoto A., Isonishi S., Ochiai K., Ohtake Y. Heat shock protein 27 was up-regulated in cisplatin resistant human ovarian tumor cell line and associated with the cisplatin resistance. Cancer Lett. 2001, 168:173-181.
20. Detcheva R.L., Kenderov A.N., Russinova A.I., Spassovska N.C., Kolev K.G., Grancharov K.C. Correlation between HSP90 induction kinetics in murine leukemia cells and the amount of cisplatin over a wide range of cytostatic concentrations. Z. Naturforsch. [C] 2002, 57:407-411.
21. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. 2002, 8:S55-S61.
22. Schulte T.W., Blagosklonny M.V., Romanova L., Mushinski J.F., Monia B.P., Johnston J.F., Nguyen P., Trepel J., Neckers L.M. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway. Mol. Cell. Biol. 1996, 16:5839-5845.
23. Blagosklonny M.V., Toretsky J., Bohen S., Neckers L. Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90. Proc. Natl. Acad. Sci. USA 1996, 93:8379-8383.
24. Sato S., Fujita N., Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc. Natl. Acad. Sci. USA 2000, 97:10832-10837.
25. An W.G., Schulte T.W., Neckers L.M. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome. Cell Growth Differ. 2000, 11:355-360.
26. Minet E., Mottet D., Michel G., Roland I., Raes M., Remacle J., Michiels C. Hypoxia-induced activation of HIF-1: role of HIF-1alpha-Hsp90 interaction. FEBS Lett. 1999, 460:251-256.
27. Pratt W.B., Toft D.O. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery (Maywood). Exp. Biol. Med. 2003, (22):111-133.
28. Solar P., Horvath V., Kleban J., Koval J., Solarova Z., Kozubik A., Fedorocko P. Hsp90 inhibitor geldanamycin increases the sensitivity of resistant ovarian adenocarcinoma cell line A2780cis to cisplatin. Neoplasma 2007, 54:127-130.
29. Grottke C., Mantwill K., Dietel M., Schadendorf D., Lage H. Identification of differentially expressed genes in human melanoma cells with acquired resistance to various antineoplastic drugs. Int. J. Cancer 2000, 88:535-546.
30. Shridhar V., Bible K.C., Staub J., Avula R., Lee Y.K., Kalli K., Huang H., Hartmann L.C., Kaufmann S.H., Smith D.I. Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer. Cancer Res. 2001, 61:4258-4265.
31. Stewart J.J., White J.T., Yan X., Collins S., Drescher C.W., Urban N.D., Hood L., Lin B. Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol. Cell Proteomics 2006, 5:433-443.
32. Strathdee G., Vass J.K., Oien K.A., Siddiqui N., Curto-Garcia J., Brown R. Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. Gynecol. Oncol. 2005, 97:898-903.
33. Dickinson D.A., Warnes G.R., Quievryn G., Messer J., Zhitkovich A., Rubitski E., Aubrecht J. Differentiation of DNA reactive and non-reactive genotoxic mechanisms using gene expression profile analysis. Mutat. Res. 2004, 549:29-41.
34. Lee K.J., Terada K., Oyadomari S., Inomata Y., Mori M., Gotoh T. Induction of molecular chaperones in carbon tetrachloride-treated rat liver: implications in protection against liver damage. Cell Stress Chaperones 2004, 9:58-68.
35. Komitowski D., Charamella L.J., Dimitrov N.V. Evaluation of nuclear morphology in adriamycin sensitive and resistant cells. Ann. Clin. Lab. Sci. 1994, 24:259-265.
36. Csermely P., Kajtar J., Hollosi M., Oikarinen J., Somogyi J. The 90kDa heat shock protein (hsp90) induces the condensation of the chromatin structure. Biochem. Biophys. Res. Commun. 1994, 202:1657-1663.
37. Dawlaty M.M., Malureanu L., Jeganathan K.B., Kao E., Sustmann C., Tahk S., Shuai K., Grosschedl R., van Deursen J.M. Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase IIalpha. Cell 2008, 133:103-115.
38. Navarro M.S., Bachant J. RanBP2: a tumor suppressor with a new twist on TopoII, SUMO, and centromeres. Cancer Cell 2008, 13:293-295.
39. Mizuno E., Iura T., Mukai A., Yoshimori T., Kitamura N., Komada M. Regulation of epidermal growth factor receptor down-regulation by UBPY-mediated deubiquitination at endosomes. Mol. Biol. Cell 2005, 16:5163-5174.
40. Berruti G., Martegani E. The deubiquitinating enzyme mUBPy interacts with the sperm-specific molecular chaperone MSJ-1: the relation with the proteasome, acrosome, and centrosome in mouse male germ cells. Biol. Reprod. 2005, 72:14-21.
41. Mathew R., Khanna R., Kumar R., Mathur M., Shukla N.K., Ralhan R. Stromelysin-2 overexpression in human esophageal squamous cell carcinoma: potential clinical implications. Cancer Detect. Prev. 2002, 26:222-228.
42. Gill J.H., Kirwan I.G., Seargent J.M., Martin S.W., Tijani S., Anikin V.A., Mearns A.J., Bibby M.C., Anthoney A., Loadman P.M. MMP-10 is overexpressed, proteolytically active, and a potential target for therapeutic intervention in human lung carcinomas. Neoplasia 2004, 6:777-785.
43. Eustace B.K., Sakurai T., Stewart J.K., Yimlamai D., Unger C., Zehetmeier C., Lain B., Torella C., Henning S.W., Beste G., Scroggins B.T., Neckers L., Ilag L.L., Jay D.G. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat. Cell Biol. 2004, 6:507-514.
44. Picard D. Hsp90 invades the outside. Nat. Cell Biol. 2004, 6:479-480.
45. Padar S., van Breemen C., Thomas D.W., Uchizono J.A., Livesey J.C., Rahimian R. Differential regulation of calcium homeostasis in adenocarcinoma cell line A549 and its Taxol-resistant subclone. Br. J. Pharmacol. 2004, 142:305-316.
46. Rizzuto R., Pinton P., Ferrari D., Chami M., Szabadkai G., Magalhaes P.J., Di Virgilio F., Pozzan T. Calcium and apoptosis: facts and hypotheses. Oncogene 2003, 22:8619-8627.
47. Maeda T., Sepe P., Lahousse S., Tamaki S., Enjoji M., Wands J.R., de la Monte S.M. Antisense oligodeoxynucleotides directed against aspartyl (asparaginyl) beta-hydroxylase suppress migration of cholangiocarcinoma cells. J. Hepatol. 2003, 38:615-622.
48. Sepe P.S., Lahousse S.A., Gemelli B., Chang H., Maeda T., Wands J.R., de la Monte S.M. Role of the aspartyl-asparaginyl-beta-hydroxylase gene in neuroblastoma cell motility. Lab. Invest. 2002, 82:881-891.
49. Lee W.J., Robinson J.A., Holman N.A., McCall M.N., Roberts-Thomson S.J., Monteith G.R. Antisense-mediated Inhibition of the plasma membrane calcium-ATPase suppresses proliferation of MCF-7 cells. J. Biol. Chem. 2005, 280:27076-27084.